World Monitor Magazine WM_November_2019_web | Page 42

EXPERT OPINION
The global pharmaceutical market will reach $1.5 trillion in 2023
and average 3-6% growth
Global Medicine Spending and Growth 2009–2023
10%
1 600
9%
1 400
7%
1 000
6%
5%
800
4%
600
3%
400
2%
200
0
8%
1 200
1%
2009
2010
2011
2012
2013
2014
2015
Spending
2016
2017
2018
2019
Growth %
2020
2021
2022
2023
0%
Forecast
Source: IQVIA Market Prognosis, Sep 2018; IQVIA Institute, Dec 2018
3
IQVIA Russia Customer Meeting 091719
and the system of reimbursing medical
services according to the principles of
a treated case, including the salary of
medical staff, the cost of medicine, even
household expense as washing ward and
others, can help balance the system. All
this leads to the effective management
of the treatment process and the
healthcare system as a whole.
What is particularly pleasing in
Kazakhstan is that the government began
to provide a diagnosis of new diseases.
After all, we learned to identify and treat
underlying conditions, reduced mortality
of newborns and women in childbirth,
which is a considerable achievement for
the country. Now we need to do more,
use artificial intelligence because we are
not talking about a pill or an injection,
we are talking about a holistic treatment
method, something beyond the pill.
Takeda talks about a holistic approach,
from prevention through vaccination
40
world monitor
to treatment and follow-up. Here we
are ready to cooperate in the diagnosis
of rare diseases, immunology and
hemophilia. We are talking about access
to new innovative treatment methods
in Kazakhstan through various access
to programmes, and we have been and
continue to be a trusted partner of the
state in providing the population with
new treatment methods. We want every
patient in Kazakhstan, in Central Asia and
the Caucasus to receive the treatment
method that best suits him.
Also, transparency and compliance are
becoming one of the global trends in
the pharmaceutical industry. The quality
and ability to track the movement of
drugs consumed in the country are also
of particular importance. Labelling of
medicines – a project that Kazakhstan is
working on – will help provide the market
with only high-quality drugs. Here we
are also pioneers, we work closely with
the Atameken Scientific and Production
Enterprise, and we are part of a pilot
project.
I see how Kazakhstan is following the
path of innovation, introducing all
the latest global trends in healthcare,
from the correct calculation of costs
to digitalisation as the introduction of
an electronic health passport. When
the whole system works, it will be a
transformational step to improve the
health and quality of life for Kazakhstan’s
entire population.
For several years, the Ministry of
Health has been actively working to
reform the healthcare system and
switch to a new model of compulsory
social healthcare insurance. How do
you think the innovations are reflected
in the market of medical products and
services? What are the expectations
from this system, and most importantly,